

10595766


=> dis his nofile;d 13 que stat;file caplus;s 13

(FILE 'HOME' ENTERED AT 15:09:41 ON 26 SEP 2007)

FILE 'REGISTRY' ENTERED AT 15:09:49 ON 26 SEP 2007

L1 STR
L2 1 SEA SSS SAM L1
L3 37 SEA SSS FUL L1

L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L3 37 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 121 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:12:13 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 25 Sep 2007 (20070925/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


L4 1 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:588963 CAPLUS Full-text
 DOCUMENT NUMBER: 143:115560
 TITLE: Preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors
 INVENTOR(S): Beyer, Thomas Arthur; Chambers, Robert James; Lam, Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David Duane
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061497	A1	20050707	WO 2004-IB4013	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303609	A1	20050707	AU 2004-303609	20041206
CA 2549510	A1	20050707	CA 2004-2549510	20041206
EP 1697356	A1	20060906	EP 2004-801323	20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1894245	A	20070110	CN 2004-80037674	20041206
BR 2004017663	A	20070403	BR 2004-17663	20041206
JP 2007513996	T	20070531	JP 2006-544574	20041206
NL 1027787	A1	20050621	NL 2004-1027787	20041215
NL 1027787	C2	20060309		
US 2007135457	A1	20070614	US 2006-595766	20060510
IN 2006DN02850	A	20070810	IN 2006-DN2850	20060519
MX 2006PA06777	A	20060823	MX 2006-PA6777	20060615
NO 2006003231	A	20060711	NO 2006-3231	20060711
PRIORITY APPLN. INFO.:			US 2003-529994P	P 20031216
			WO 2004-IB4013	W 20041206

GI



AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aminoarom. substitution of chloropyrimide II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

IT 857521-01-4P 857521-02-9P 857521-03-0P
 857521-04-1P 857521-05-2P 857521-06-3P
 857521-07-4P 857521-08-5P 857521-09-6P
 857521-10-9P 857521-11-0P 857521-12-1P
 857521-13-2P 857521-14-3P 857521-15-4P
 857521-16-5P 857521-17-6P 857521-18-7P
 857521-19-8P 857521-20-1P 857521-21-2P
 857521-22-3P 857521-23-4P 857521-24-5P
 857521-25-6P 857521-26-7P 857521-27-8P
 857521-28-9P 857521-29-0P 857521-30-3P
 857521-31-4P 857521-32-5P 857521-33-6P
 857521-34-7P 857521-35-8P 857521-36-9P
 857521-37-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors)

RN 857521-01-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-02-9 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-03-0 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-04-1 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)

10595766




RN 857521-05-2 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N,N'-bis[(3,5-dimethoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 857521-06-3 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-
[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 857521-07-4 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-
(3-phenylpropyl)- (CA INDEX NAME)

10595766




RN 857521-08-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[(4-chlorophenyl)methyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-09-6 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(phenylmethyl)- (CA INDEX NAME)



RN 857521-10-9 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-11-0 CAPLUS

CN Benzenemethanol, 4-[[[4-[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α,α-dimethyl- (CA INDEX NAME)



RN 857521-12-1 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-13-2 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[2-(3,5-dimethoxyphenyl)ethyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)

10595766




RN 857521-14-3 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-15-4 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-16-5 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-17-6 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-18-7 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 857521-19-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenoxyethyl)- (CA INDEX NAME)

10595766




RN 857521-20-1 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[[2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)



RN 857521-21-2 CAPLUS


CN Benzenemethanol, 4-[2-[[4-[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]- α,α -dimethyl- (CA INDEX NAME)



RN 857521-22-3 CAPLUS


CN Benzenemethanol, 4-[2-[[4-[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]- α,α -dimethyl- (CA INDEX NAME)

10595766




RN 857521-23-4 CAPLUS

CN Benzenemethanol, 4-[[4-[[[(3,5-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]methyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-24-5 CAPLUS


CN Ethanone, 1-[4-[3-[[4-[[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 857521-25-6 CAPLUS


CN Benzenemethanol, 4-[3-[[4-[[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-(trifluoromethyl)- (CA INDEX NAME)

10595766




RN 857521-26-7 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(2,1,3-benzoxadiazol-5-yl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-27-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(6-benzothiazolyl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-28-9 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[3-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]propyl]- (CA INDEX NAME)

10595766




RN 857521-29-0 CAPLUS

CN Benzenemethanol, 3-[3-[[4-[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]-α-methyl- (CA INDEX NAME)



RN 857521-30-3 CAPLUS


CN Benzonitrile, 4-[3-[[4-[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]- (CA INDEX NAME)



RN 857521-31-4 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)

10595766




RN 857521-32-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-33-6 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 857521-34-7 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3-ethoxy-4-methoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)

10595766




RN 857521-35-8 CAPLUS

CN Benzenemethanol, 4-[3-[[4-[[[(3-ethoxy-4-methoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]- α -methyl- (CA INDEX NAME)



RN 857521-36-9 CAPLUS

CN Ethanone, 1-[4-[3-[[4-[[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]propyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 857521-37-0 CAPLUS

CN Ethanone, 1-[3-[3-[[4-[[[(3,4-dimethoxyphenyl)methyl]amino]pyrido[2,3-

10595766

d[pyrimidin-2-yl]amino]propyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil medl, BIOSIS, EMBASE, CAPLUS; S Beyer T?/AU; S Chambers R?/AU; S Lam K?/AU; S Westerly M?/AU; S Morrell A?/AU; S Thompson D?/AU

FILE 'MEDLINE' ENTERED AT 15:13:22 ON 26 SEP 2007

FILE 'BIOSIS' ENTERED AT 15:13:22 ON 26 SEP 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:13:22 ON 26 SEP 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:13:22 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

L5	188 FILE MEDLINE
L6	247 FILE BIOSIS
L7	168 FILE EMBASE
L8	158 FILE CAPLUS

TOTAL FOR ALL FILES
L9 761 BEYER T?/AU

L10	483 FILE MEDLINE
L11	713 FILE BIOSIS
L12	354 FILE EMBASE
L13	1052 FILE CAPLUS

TOTAL FOR ALL FILES
L14 2602 CHAMBERS R?/AU

L15	1469 FILE MEDLINE
L16	1572 FILE BIOSIS
L17	1315 FILE EMBASE
L18	1264 FILE CAPLUS

10595766

TOTAL FOR ALL FILES

L19 5620 LAM K?/AU

NOTE (120-124 deleted)

L25 53 FILE MEDLINE

L26 67 FILE BIOSIS

L27 64 FILE EMBASE

L28 53 FILE CAPLUS

TOTAL FOR ALL FILES

L29 237 MORRELL A?/AU

L30 2948 FILE MEDLINE

L31 3971 FILE BIOSIS

L32 2212 FILE EMBASE

L33 4092 FILE CAPLUS

TOTAL FOR ALL FILES

L34 13223 THOMPSON D?/AU

=> s l9 and l14 and l19 and l29 and l34;s li m?/au

L35 0 FILE MEDLINE

L36 0 FILE BIOSIS

L37 0 FILE EMBASE

L38 1 FILE CAPLUS

TOTAL FOR ALL FILES

L39 1 L9 AND L14 AND L19 AND L29 AND L34

L40 4567 FILE MEDLINE

L41 5087 FILE BIOSIS

L42 3613 FILE EMBASE

L43 15811 FILE CAPLUS

TOTAL FOR ALL FILES

L44 29078 LI M?/AU

=> s l44 and l39

L45 0 FILE MEDLINE

L46 0 FILE BIOSIS

L47 0 FILE EMBASE

L48 1 FILE CAPLUS

TOTAL FOR ALL FILES

L49 1 L44 AND L39

=> s l49 not l4

L50 0 FILE MEDLINE

L51 0 FILE BIOSIS

L52 0 FILE EMBASE

L53 0 FILE CAPLUS

TOTAL FOR ALL FILES

L54 0 L49 NOT L4

10595766

=> s l4

```
L55      0 FILE MEDLINE
L56      0 FILE BIOSIS
L57      0 FILE EMBASE
L58      1 FILE CAPLUS
```

TOTAL FOR ALL FILES

```
L59      1 L4
```

=> fil reg;e "pyrido[2,3-d]pyrimidine-2,4-diamine"/cn 5

FILE 'REGISTRY' ENTERED AT 15:14:49 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9
DICTIONARY FILE UPDATES: 25 SEP 2007 HIGHEST RN 948051-90-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
E1      1      PYRIDIDIUM, 4-STYRYL-1-VINYL-/CN
E2      1      PYRIDIDIUM, 4-STYRYL-1-VINYL-, P-TOLUENESULFONATE/CN
E3      0 --> PYRIDO2,3-DPYRIMIDINE-2,4-DIAMINE/CN
E4      1      PYRIDO(1'',2''':1'',2'')IMIDAZO(4'',5''':3',4')CYCLOPENTA(1',
,2':5,6)NAPHTH(1,2-D)AZEPIN-2(3H)-ONE, 4,5,5A,5B,6,7,7A,14,1
4A,14B,15,16-DODECAHYDRO-5A,7A,10-TRIMETHYL-, (5AR-(5A.ALPHA
.,5BB,7AA/CN
E5      1      PYRIDO(1'',2''':1'',2'')IMIDAZO(4'',5''':3',4')CYCLOPENTA(1',
,2':5,6)NAPHTH(1,2-D)AZEPIN-2(3H)-ONE, 4,5,5A,5B,6,7,7A,14,1
4A,14B,15,16-DODECAHYDRO-5A,7A,11-TRIMETHYL-, (5AR-(5A.ALPHA
.,5BB,7AA/CN
```

=> s pyrido(l)pyrimidine(l)diamine

```
273116 PYRIDO
619275 PYRIMIDINE
358987 DIAMINE
74 DIAMINES
358987 DIAMINE
(DIAMINE OR DIAMINES)
L60      1433 PYRIDO(L)PYRIMIDINE(L)DIAMINE
```

=> fil medl,biosis,embase,caplus;s l60 or pyrido(7a)pyrimidine(5a)diamine

10595766

FILE 'MEDLINE' ENTERED AT 15:16:39 ON 26 SEP 2007

FILE 'BIOSIS' ENTERED AT 15:16:39 ON 26 SEP 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:16:39 ON 26 SEP 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:16:39 ON 26 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

L61 90 FILE MEDLINE
L62 156 FILE BIOSIS
L63 380 FILE EMBASE
L64 478 FILE CAPLUS

TOTAL FOR ALL FILES

L65 1104 L60 OR PYRIDO(7A) PYRIMIDINE(5A) DIAMINE

=> s pde2 or phosphodiesterase

L66 26278 FILE MEDLINE
L67 24560 FILE BIOSIS
L68 26236 FILE EMBASE
L69 27972 FILE CAPLUS

TOTAL FOR ALL FILES

L70 105046 PDE2 OR PHOSPHODIESTERASE

=> s l65 and l70

L71 0 FILE MEDLINE
L72 0 FILE BIOSIS
L73 0 FILE EMBASE
L74 6 FILE CAPLUS

TOTAL FOR ALL FILES

L75 6 L65 AND L70

=> d l-6 ibib abs hitstr

L75 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:173503 CAPLUS Full-text

DOCUMENT NUMBER: 146:229376

TITLE: Preparation of fused pyridofuopyrimidines as
phosphodiesterase 4 (PDE4) inhibitors.

INVENTOR(S): Taltavull Moll, Joan; Pages Santacana, Luis Miquel

PATENT ASSIGNEE(S): Almirall Prodesfarma, S. A., Spain

SOURCE: PCT Int. Appl., 61pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017078	A1	20070215	WO 2006-EP7218	20060721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

ES 2281251

A1 20070916

ES 2005-1840

20050727

PRIORITY APPLN. INFO.:


ES 2005-1840

A 20050727

OTHER SOURCE(S):

MARPAT 146:229376

GI



AB Title compds. [I; G1 = CR6R7, O; R6, R7 = H, alkyl; R1, R2 = H, alkyl; R3 = (substituted) alkyl, alkoxy, amino, OH, alkylamino, dialkylamino, cycloalkylamino, aryl, heteroaryl, saturated N-bonded heterocyclyl; R4, R5 = H, alkyl, hydroxyalkyl, etc.], were prepared Thus, N5-isopropyl-2,2-dimethyl-N8-(2-morpholin-4-ylethyl)-1,2,3,4-tetrahydropyrimido[4',5':4,5]furo[2,3-c]isoquinoline-5,8-diamine (preparation outlined) inhibited PDE4 with IC50 = 0.2 nM.

IT 925214-07-9P 925214-08-0P 925214-09-1P

925214-11-5P 925214-12-6P 925214-43-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyridofuropyrimidines as PDE4 inhibitors)

RN 925214-07-9 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

10595766




RN 925214-08-0 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 925214-09-1 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, N8-[(2,3-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



RN 925214-11-5 CAPLUS


10595766

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-[2-(4-morpholinyl)ethyl]-N8-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 925214-12-6 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, N8-[(3,4-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



RN 925214-43-3 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




IT 925214-72-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused pyridofuopyrimidines as PDE4 inhibitors)

RN 925214-72-8 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]furo[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]-N5-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:542483 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:28003

TITLE: New pyridothienopyrimidine derivatives, their preparation and use as PDE4 inhibitors for the treatment of pathological diseases

INVENTOR(S): Pages Santacana, Luis Miquel; Taltavull Moll, Joan; Gracia Ferrer, Jordi

PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

10595766

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058723	A1	20060608	WO 2005-EP12773	20051130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM ES 2259892 A1 20061016 ES 2004-2877 20041130 AU 2005311422 A1 20060608 AU 2005-311422 20051130 CA 2588808 A1 20060608 CA 2005-2588808 20051130 EP 1819712 A1 20070822 EP 2005-813317 20051130 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU PRIORITY APPLN. INFO.: ES 2004-2877 A 20041130 WO 2005-EP12773 W 20051130 OTHER SOURCE(S): MARPAT 145:28003 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the use of a pyrido[3',2':4,5]thieno[3,2-d]pyrimidine derivative I [X = (CH₂)_n; n = 0-1; R₁, R₂ = independently H, alkyl; R₃ = (un)substituted alkyl, monoalkyl/dialkyl/amino, hetero/aryl, etc.; R₄, R₅ = independently H, alkyl, -(CR₈R₉)p-A-(CR₁₀R₁₁)q-G₂; p, q = independently 1-3; A = a bond, O, OCO, etc.; R₈-R₁₁ = independently H, alkyl; G₂ = (un)substituted hetero/aryl, heterocyclyl] and their pharmaceutically acceptable salts and N-oxides, in the manufacture of a medicament for the treatment or prevention of a pathol. condition or disease susceptible to amelioration by inhibition of Phosphodiesterase 4 (PDE4). The invention is also related to the preparation of pyridothienopyrimidines I. Four pharmaceutical compns. are given. For example, II was prepared by cyclocondensation of thiopyridine III (preparation given) with 2-chloroacetamide, cyclization with Et orthoformate, chlorination, and amination of chloride with 4-pyridinemethanamine. Preferred I exhibited an IC₅₀ value < 30 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).


IT 889657-27-6P 889657-28-7P 889657-49-2P
 889657-50-5P 889657-51-6P 889657-52-7P
 889657-53-8P 889657-54-9P 889657-70-9P
 889657-71-0P 889657-73-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10595766

(drug candidate; preparation of pyrido[3,2-d]pyrimidines as PDE4 inhibitors for treating pathol. diseases)


RN 889657-27-6 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N-(2-methoxyethyl)-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 889657-28-7 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N-(2-methoxyethyl)-N,2,2-trimethyl-N'-[3-pyridinylmethyl]- (9CI) (CA INDEX NAME)



RN 889657-49-2 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,N,2,2-tetramethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

10595766




RN 889657-50-5 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,N,2,2-tetramethyl-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 889657-51-6 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, N8-[(2,3-dimethoxyphenyl)methyl]-1,4-dihydro-N5,N5,2,2-tetramethyl- (CA INDEX NAME)



10595766


RN 889657-52-7 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-53-8 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 889657-54-9 CAPLUS


CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,N5,2,2-tetramethyl-N8-(2-pyridinylmethyl)- (CA INDEX NAME)

10595766




RN 889657-70-9 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 889657-71-0 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 889657-73-2 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-

10595766

diamine, 1,4-dihydro-N5,2,2-trimethyl-N8-[2-(4-morpholinyl)ethyl]-N8-(3-pyridinylmethyl)- (CA INDEX NAME)



IT 889656-87-5P 889656-88-6P 889656-90-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridothienopyrimidines as PDE4 inhibitors

for treating pathol. diseases)


RN 889656-87-5 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 889656-88-6 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N-(phenylmethyl)-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 889656-90-0 CAPLUS

CN 2H-Pyrano[4'',3'':4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-5,8-diamine, 1,4-dihydro-N,2,2-trimethyl-N'-(2-(4-morpholinyl)ethyl)-N-(phenylmethyl)-N'-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on SIN

ACCESSION NUMBER: 2006:539368 CAPLUS Full-text

DOCUMENT NUMBER: 145:46072

TITLE: New pyridothienopyrimidine derivatives, their preparation and use as PDE4 inhibitors for the treatment of pathological diseases

INVENTOR(S): Pages Santacana, Lluís Miquel; Taltavull Mollí, Joan

PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006058724	A1	20060608	WO 2005-EP12774	20051130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 ES 2259891 A1 20061016 ES 2004-2876 20041130
 AU 2005311423 A1 20060608 AU 2005-311423 20051130
 CA 2588741 A1 20060608 CA 2005-2588741 20051130
 EP 1819710 A1 20070822 EP 2005-814833 20051130
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 IN 2007DN03938 A 20070831 IN 2007-DN3938 20070525
 PRIORITY APPLN. INFO.: ES 2004-2876 A 20041130
 WO 2005-EP12774 W 20051130
 OTHER SOURCE(S): MARPAT 145:46072
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the use of a pyridothienopyrimidine derivative I
 [X = (G1)_m; G1 = CR6R7, NR6; R6, R7 = independently H, alkyl; Y = (CH2)_n; m, n
 = independently 0-1; R1, R2 = independently H, alkyl; R3 = (un)substituted
 alkyl, monoalkyl/dialkyl/amino, heteroaryl, etc.; R4, R5 = independently H,
 alkyl, -(CR8R9)p-A-(CR10R11)q-G2; p, q = independently 1-3; A = a bond, O, OCO
 , etc.; R8-R11 = independently H, alkyl; G2 = (un)substituted heteroaryl,
 heterocyclyl, and their pharmaceutically acceptable salts and N-oxides, in
 the manufacture of a medicament for the treatment or prevention of a pathol.
 condition or disease susceptible to amelioration by inhibition of
 Phosphodiesterase 4 (PDE4). The invention is also related to the preparation
 of pyridothienopyrimidines I. Four pharmaceutical compns. are given. For
 example, II was prepared by cyclocondensation of thiopyridine III with 2-
 chloroacetamide, cyclization with Et orthoformate, chlorination, and amination
 of the chloride with [2-(morpholin-4-yl)ethyl]amine. Preferred I exhibited an
 IC50 value < 30 nM for the inhibition of PDE4. I and their pharmaceutical
 compns. are useful for prevention and treatment of asthma, chronic obstructive
 pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and
 irritable bowel disease (no data).

IT 890024-43-6P 890024-44-9P 890024-46-1P
 890024-48-3P 890024-49-4P 890024-52-9P
 890024-53-8P 890024-54-1P 890024-64-3P
 890024-66-5P 890024-68-7P 890024-71-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of pyridothienopyrimidines as PDE4 inhibitors
 for treating pathol. diseases)


RN 890024-43-8 CAPLUS
 CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
 2,3-dihydro-N4,N4,2,2-tetramethyl-N7-[2-(4-morpholinyl)ethyl]- (CA INDEX
 NAME)

10595766




RN 890024-44-9 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
2,3-dihydro-N4,N4,2,2-tetramethyl-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 890024-46-1 CAPLUS


CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N7-(2-furanylmethyl)-2,3-dihydro-N4,N4,2,2-tetramethyl- (CA INDEX NAME)



RN 890024-48-3 CAPLUS


CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
2,3-dihydro-N4,N4,1,1-tetramethyl-N7-[2-(4-morpholinyl)ethyl]- (CA INDEX
NAME)

10595766




RN 890024-49-4 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
2,3-dihydro-N4,N4,1,1-tetramethyl-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 890024-52-9 CAPLUS


CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
2,3-dihydro-N7-[2-(1H-imidazol-4-yl)ethyl]-N4,N4,1,1-tetramethyl- (9CI)
(CA INDEX NAME)



RN 890024-53-0 CAPLUS


10595766

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N7-(2-furanylmethyl)-2,3-dihydro-N4,N4,1,1-tetramethyl- (CA INDEX NAME)




RN 890024-54-1 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N7-[(2,3-dimethoxyphenyl)methyl]-2,3-dihydro-N4,N4,1,1-tetramethyl- (CA
INDEX NAME)



RN 890024-64-3 CAPLUS


CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N-ethyl-2,3-dihydro-N,2,2-trimethyl-N'-[2-(4-morpholinyl)ethyl]- (9CI)
(CA INDEX NAME)



10595766


RN 890024-66-5 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N-ethyl-2,3-dihydro-N,2,2-trimethyl-N'-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)




RN 890024-68-7 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N'-[(2,3-dimethoxyphenyl)methyl]-N-ethyl-2,3-dihydro-N,2,2-trimethyl-
(9CI) (CA INDEX NAME)



RN 890024-71-2 CAPLUS

CN 1H-Cyclopenta[4',5']pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-4,7-diamine,
N4-ethyl-2,3-dihydro-N4,2,2-trimethyl-N7-[2-(4-morpholinyl)ethyl]-N7-(3-
pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on SIN

ACCESSION NUMBER: 2005:588963 CAPLUS Full-text

DOCUMENT NUMBER: 143:115560

TITLE: Preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors

INVENTOR(S): Beyer, Thomas Arthur; Chambers, Robert James; Lam, Kelvin; Li, Mei; Morrell, Andrew Ian; Thompson, David Duane

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061497	A1	20050707	WO 2004-IB4013	20041206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303609	A1	20050707	AU 2004-303609	20041206
CA 2549510	A1	20050707	CA 2004-2549510	20041206
EP 1697356	A1	20060906	EP 2004-801323	20041206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1894245	A	20070110	CN 2004-80037674	20041206
BR 2004017663	A	20070403	BR 2004-17663	20041206
JP 2007513996	T	20070531	JP 2006-544574	20041206
NL 1027787	A1	20050621	NL 2004-1027787	20041215
NL 1027787	C2	20060309		

US 2007135457	A1	20070614	US 2006-595766		20060510
IN 2006DN02850	A	20070810	IN 2006-DN2850		20060519
MX 2006PA06777	A	20060823	MX 2006-PA6777		20060615
NO 2006003231	A	20060711	NO 2006-3231		20060711
PRIORITY APPLN. INFO.:			US 2003-529994P	P	20031216
			WO 2004-IB4013	W	20041206
GI					



AB Title compds. I [Z = O-alkyl; R1, R2 = H, OCH3 with provisos; n = 1-4; X = a bond, O, S, etc.; Y = benzoxazolyl, benzothiazolyl, benzofurazanyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, aminoarom. substitution of chloropyrimidine II and 2-(2-aminoethyl)pyridine afforded pyrido[2,3-d]pyrimidine III in 40% yield. In PDE 2 inhibition assays, 4 - examples of compds. I exhibited IC50 values <50 nM.

IT	857521-01-8P	857521-02-9P	857521-03-0P
	857521-04-1P	857521-05-2P	857521-06-3P
	857521-07-4P	857521-08-5P	857521-09-6P
	857521-10-9P	857521-12-1P	857521-13-2P
	857521-14-3P	857521-15-4P	857521-16-5P
	857521-17-6P	857521-18-7P	857521-19-8P
	857521-20-1P	857521-26-7P	857521-27-8P
	857521-28-9P	857521-31-4P	857521-32-5P
	857521-33-6P	857521-34-7P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrido[2,3-d]pyrimidine-2,4-diamines as PDE-2 inhibitors)

RN 857521-01-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-02-9 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-03-0 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)



RN 857521-04-1 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)

10595766




RN 857521-05-2 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N,N'-bis[(3,5-dimethoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 857521-06-3 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-
[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 857521-07-4 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-
(3-phenylpropyl)- (CA INDEX NAME)

10595766




RN 857521-08-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[(4-chlorophenyl)methyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-09-6 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(phenylmethyl)- (CA INDEX NAME)



RN 857521-10-9 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-12-1 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)



RN 857521-13-2 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[2-(3,5-dimethoxyphenyl)ethyl]-N4-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-14-3 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(3-fluorophenyl)ethyl]- (CA INDEX NAME)

10595766




RN 857521-15-4 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-16-5 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 857521-17-6 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenylethyl)- (CA INDEX NAME)

10595766




RN 857521-18-7 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 857521-19-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(2-phenoxyethyl)- (CA INDEX NAME)



RN 857521-20-1 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)

10595766




RN 857521-26-7 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(2,1,3-benzoxadiazol-5-yl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-27-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N2-[3-(6-benzothiazolyl)propyl]-N4-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 857521-28-9 CAPLUS


CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-[3-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]propyl]- (CA INDEX NAME)

10595766




RN 857521-31-4 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-[3-(4-pyridinyl)propyl]- (CA INDEX NAME)




RN 857521-32-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,4-dimethoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)




RN 857521-33-6 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3,5-dimethoxyphenyl)methyl]-N2-(3-phenoxypropyl)- (CA INDEX NAME)



RN 857521-34-7 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4-diamine, N4-[(3-ethoxy-4-methoxyphenyl)methyl]-N2-(3-phenylpropyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:563288 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:307967

TITLE: New Base Pairing Motifs. The Synthesis and Thermal Stability of Oligodeoxynucleotides Containing Imidazopyridopyrimidine Nucleosides with the Ability to Form Four Hydrogen Bonds

AUTHOR(S): Minakawa, Noriaki; Kojima, Naoshi; Hikishima, Sadao; Sasaki, Takashi; Kiyosue, Arihiro; Atsumi, Naoko; Ueno, Yoshihito; Matsuda, Akira

CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan

SOURCE: Journal of the American Chemical Society (2003), 125(33), 9970-9982

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:307967

AB The synthesis and thermal stability of oligodeoxynucleotides (ODNs) containing imidazo[5',4':4,5]pyrido[2,3-d]pyrimidine nucleosides 1-4 (NN, OO, NO, and ON, resp.) with the aim of developing two sets of new base pairing motifs consisting of four hydrogen bonds (H-bonds) is described. The proposed four tricyclic nucleosides were synthesized through the Stille coupling reaction of a 5-iodoimidazole nucleoside with an appropriate 5-stannylpyrimidine derivative, followed by an intramol. cyclization. These nucleosides were

incorporated into ODNs to investigate the H-bonding ability. When one mol. of the tricyclic nucleosides was incorporated into the center of each 17mer ODNs, no apparent specificity of base pairing was observed, and all duplexes were less stable than the duplexes containing natural G:C and A:T pairs. On the other hand, when three mols. of the tricyclic nucleosides were consecutively incorporated into the center of each 17mer ODNs, thermal and thermodyn. stabilization of the duplexes due to the specific base pairings was observed. The melting temperature (T_m) of the duplex containing the NO:ON pairs showed the highest T_m of 84.0 °C, which was 18.2 and 23.5 °C higher than that of the duplexes containing G:C and A:T pairs, resp. This result implies that NO and ON form base pairs with four H-bonds when they are incorporated into ODNs. The duplex containing NO:ON pairs was markedly stabilized by the assistance of the stacking ability of the imidazopyridopyrimidine bases. Thus, we developed a thermally stable new base pairing motif, which should be useful for the stabilization and regulation of a variety of DNA structures.

IT 597551-46-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and thermal stability of oligodeoxyribonucleotides containing imidazopyridopyrimidine nucleosides with ability to form four hydrogen bonds)

RN 597551-46-7 CAPLUS


CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7(5H,6H)-dione,
1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-pentofuranosyl]-, compd. with 1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-pentofuranosyl]-1H-imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 597551-36-5

CMF C31 H53 N5 O5 Si2

Absolute stereochemistry.




CM 2

CRN 597551-28-5

CMF C31 H55 N7 O3 Si2

Absolute stereochemistry.



IT 597551-28-5P 597551-30-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and thermal stability of oligodeoxyribonucleotides containing imidazopyridopyrimidine nucleosides with ability to form four hydrogen bonds)

RN 597551-28-5 CAPLUS

CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine,
1-[2-deoxy-3,5-bis-O-[tris(1-methylethyl)silyl]-β-D-erythro-
pentofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597551-30-9 CAPLUS

CN 1H-Imidazo[4',5':4,5]pyrido[2,3-d]pyrimidine-4,7-diamine,
1-(2-deoxy-β-D-erythro-pentofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:


77

THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L75 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:124400 CAPLUS Full-text
 DOCUMENT NUMBER: 120:124400
 TITLE: Chemical synthesis of new pyridine derivatives acting
 as inhibitors of phosphodiesterase
 AUTHOR(S): Pallas, M.; Jimenez, A.; Victory, P.; Borrell, J. I.;
 Vidal-Ferran, A.; Escubedo, E.; Camarasa, J.
 CORPORATE SOURCE: Fac. Pharm., Univ. Barcelona, Barcelona, E-08028,
 Spain
 SOURCE: Pharmaceutical and Pharmacological Letters (1993),
 3(1), 36-9
 CODEN: PPLEE3; ISSN: 0939-9488
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The chemical synthesis of new pyridine derivs. and their pharmacol. activity
 as inhibitors of phosphodiesterase are reported. Among them IQS-4 was the
 most potent inhibitor (IC₅₀ 5.8 μM) and this effect has a good correlation
 with a relaxant effect on carbachol-contracted guinea-pig trachea (IC₅₀ 73.4
 μM). A preferential effect of these compds. on phosphodiesterase type IV was
 deduced are reported.
 IT 20732-44-9E, IQS 2
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and phosphodiesterase inhibitory activity of)
 RN 20732-44-9 CAPLUS
 CN Pyrido[2,3-d]pyrimidine-2,4-diamine, 5,7-diphenyl- (9CI) (CA INDEX NAME)



=> dis his nofile

(FILE 'HOME' ENTERED AT 15:09:41 ON 26 SEP 2007)

FILE 'REGISTRY' ENTERED AT 15:09:49 ON 26 SEP 2007

L1 STR
 L2 1 SEA SSS SAM L1
 L3 3/ SEA SSS FUL L1
 D L3 QUE STAT

```

FILE 'CAPLUS' ENTERED AT 15:12:13 ON 26 SEP 2007
L4      1 SEA ABB=ON PLU=ON L3
        D IBIB ABS HITSTR

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 15:13:22 ON 26 SEP 2007
L5      188 SEA ABB=ON PLU=ON BEYER T?/AU
L6      247 SEA ABB=ON PLU=ON BEYER T?/AU
L7      168 SEA ABB=ON PLU=ON BEYER T?/AU
L8      158 SEA ABB=ON PLU=ON BEYER T?/AU
TOTAL FOR ALL FILES
L9      761 SEA ABB=ON PLU=ON BEYER T?/AU
L10     483 SEA ABB=ON PLU=ON CHAMBERS R?/AU
L11     713 SEA ABB=ON PLU=ON CHAMBERS R?/AU
L12     354 SEA ABB=ON PLU=ON CHAMBERS R?/AU
L13     1052 SEA ABB=ON PLU=ON CHAMBERS R?/AU
TOTAL FOR ALL FILES
L14     2602 SEA ABB=ON PLU=ON CHAMBERS R?/AU
L15     1469 SEA ABB=ON PLU=ON LAM K?/AU
L16     1572 SEA ABB=ON PLU=ON LAM K?/AU
L17     1315 SEA ABB=ON PLU=ON LAM K?/AU
L18     1264 SEA ABB=ON PLU=ON LAM K?/AU
TOTAL FOR ALL FILES
L19     5620 SEA ABB=ON PLU=ON LAM K?/AU
120-124 deleted
L25     53 SEA ABB=ON PLU=ON MORRELL A?/AU
L26     67 SEA ABB=ON PLU=ON MORRELL A?/AU
L27     64 SEA ABB=ON PLU=ON MORRELL A?/AU
L28     53 SEA ABB=ON PLU=ON MORRELL A?/AU
TOTAL FOR ALL FILES
L29     237 SEA ABB=ON PLU=ON MORRELL A?/AU
L30     2948 SEA ABB=ON PLU=ON THOMPSON D?/AU
L31     3971 SEA ABB=ON PLU=ON THOMPSON D?/AU
L32     2212 SEA ABB=ON PLU=ON THOMPSON D?/AU
L33     4092 SEA ABB=ON PLU=ON THOMPSON D?/AU
TOTAL FOR ALL FILES
L34     13223 SEA ABB=ON PLU=ON THOMPSON D?/AU
L35     0 SEA ABB=ON PLU=ON L5 AND L10 AND L15 AND L25 AND L30
L36     0 SEA ABB=ON PLU=ON L6 AND L11 AND L16 AND L26 AND L31
L37     0 SEA ABB=ON PLU=ON L7 AND L12 AND L17 AND L27 AND L32
L38     1 SEA ABB=ON PLU=ON L8 AND L13 AND L18 AND L28 AND L33
TOTAL FOR ALL FILES
L39     1 SEA ABB=ON PLU=ON L9 AND L14 AND L19 AND L29 AND L34
L40     4567 SEA ABB=ON PLU=ON LI M?/AU
L41     5087 SEA ABB=ON PLU=ON LI M?/AU
L42     3613 SEA ABB=ON PLU=ON LI M?/AU
L43     15811 SEA ABB=ON PLU=ON LI M?/AU
TOTAL FOR ALL FILES
L44     29078 SEA ABB=ON PLU=ON LI M?/AU
L45     0 SEA ABB=ON PLU=ON L40 AND L35
L46     0 SEA ABB=ON PLU=ON L41 AND L36
L47     0 SEA ABB=ON PLU=ON L42 AND L37
L48     1 SEA ABB=ON PLU=ON L43 AND L38
TOTAL FOR ALL FILES
L49     1 SEA ABB=ON PLU=ON L44 AND L39
L50     0 SEA ABB=ON PLU=ON L45 NOT L4
L51     0 SEA ABB=ON PLU=ON L46 NOT L4
L52     0 SEA ABB=ON PLU=ON L47 NOT L4
L53     0 SEA ABB=ON PLU=ON L48 NOT L4
TOTAL FOR ALL FILES

```

10595766

```

L54      0 SEA ABB=ON PLU=ON L49 NOT L4
L55      0 SEA ABB=ON PLU=ON L3
L56      0 SEA ABB=ON PLU=ON L3
L57      0 SEA ABB=ON PLU=ON L3
L58      1 SEA ABB=ON PLU=ON L3
TOTAL FOR ALL FILES
L59      1 SEA ABB=ON PLU=ON L4

```

FILE 'REGISTRY' ENTERED AT 15:14:49 ON 26 SEP 2007

E "PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE"/CN 5

L60 1433 SEA ABB=ON PLU=ON PYRIDO(L)PYRIMIDINE(L)DIAMINE

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 15:16:39 ON 26 SEP 2007

L61 90 SEA ABB=ON PLU=ON L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE

L62 156 SEA ABB=ON PLU=ON L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE

L63 380 SEA ABB=ON PLU=ON L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE

L64 478 SEA ABB=ON PLU=ON L60 OR PYRIDO(7A)PYRIMIDINE(5A)DIAMINE

TOTAL FOR ALL FILES

L65 1104 SEA ABB=ON PLU=ON L60 OR PYRIDO(7A) PYRIMIDINE(5A) DIAMINE

L66 26278 SEA ABB=ON PLU=ON PDE2 OR PHOSPHODIESTERASE

L67 24560 SEA ABB=ON PLU=ON PDE2 OR PHOSPHODIESTERASE

L68	26236	SEA	ABB=ON	PLU=ON	PDE2	OR	PHOSPHODIESTERASE
-----	-------	-----	--------	--------	------	----	-------------------

L69	27972	SEA	ABB=ON	PLU=ON	PDE2	OR	PHOSPHODIESTERASE
-----	-------	-----	--------	--------	------	----	-------------------

TOTAL FOR ALL FILES

L70 105046 SEA ABB=ON PLU=ON PDE2 OR PHOSPHODIESTERASE

L71 0 SEA ABB=ON PLU=ON L61 AND L66

L72 0 SEA ABB=ON PLU=ON L62 AND L67

```
L73      0 SEA ABB=ON  PLU=ON  L63 AND L68
```

L74 6 SEA ABB=ON PLU=ON L64 AND L69


TOTAL FOR ALL FILES

L75 6 SEA ABB=ON PLU=ON L65 AND L70

D 1-6 IBIB ABS HITSTR

```
=> d 13 que stat;d 160 que stat
```

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

```

L3          37 SEA FILE=REGISTRY SSS EUL L1

```

100.0% PROCESSED 121 ITERATIONS

SEARCH TIME: 00.00.01

37 ANSWERS

10595766

L60 1433 SEA FILE=REGISTRY ABB=ON PLU=ON PYRIDO(L)PYRIMIDINE(L)DIAMINE

=> log y

STN INTERNATIONAL LOGOFF AT 15:18:11 ON 26 SEP 2007